WATERTOWN, Mass. - C4 Therapeutics, Inc. (NASDAQ: CCCC), a clinical-stage biopharmaceutical company with a market capitalization of $247 million, has announced its anticipated milestones for 2025, focusing on advancing its protein degradation therapies. According to InvestingPro data, the company's stock is currently trading near its 52-week low, having declined nearly 49% over the past year. The company is poised to complete important phases in its clinical development programs for several drug candidates, including cemsidomide for multiple myeloma and non-Hodgkin’s lymphoma, and CFT1946 for BRAF V600X solid tumors.
Cemsidomide has completed its Phase 1 dose escalation, with data expected in the second half of 2025. The drug is being prepared for the next phase of clinical development in combination with dexamethasone and other agents for multiple myeloma, with studies expected to initiate in early 2026. Additionally, expansion cohort(s) for peripheral T-cell lymphoma are set to open in the second half of 2025.
CFT1946 is advancing through its Phase 1 trial, with dose escalation set to complete in the first half of 2025. Data from the study, which includes monotherapy in melanoma and combinations with cetuximab in colorectal cancer and trametinib in melanoma, are anticipated in the second half of the year.
The company's partner, Betta Pharmaceuticals, is progressing with the Phase 1 dose escalation study of CFT8919 in Greater China. The data will inform future development plans for non-small cell lung cancer patients with the EGFR L858R mutation.
C4 Therapeutics expects its current financial resources to fund operations into 2027. The company's TORPEDO® platform continues to be utilized to develop orally bioavailable degraders for oncology and non-oncology targets, with plans to present and publish preclinical work and advance internal and collaboration programs to key milestones.
In 2024, C4 Therapeutics reported significant progress in its clinical trials, including promising data from cemsidomide studies presented at the American Society of Hematology Annual Meeting. With 12 additional exclusive insights available on InvestingPro, investors can access detailed analysis of the company's financial health score of 2.12, labeled as 'FAIR' by InvestingPro analysts. The company also showcased its expertise in drug discovery and strengthened its leadership team and Board of Directors to support its growth as a fully integrated biotechnology company.
This report is based on a press release statement, which outlined the company's strategic clinical developments and achievements without providing specific financial details or market impact analysis.
In other recent news, C4 Therapeutics has reported encouraging data from early-stage trials of its cancer drug, cemsidomide. The drug showed a promising overall response rate in trials treating relapsed or refractory multiple myeloma and Non-Hodgkin’s Lymphoma. Analysts from Jefferies and Stifel expressed optimism about the trial outcomes, maintaining a buy rating on the company.
In other developments, C4 Therapeutics has seen changes in its leadership. Steve Hoerter, a seasoned industry leader, has joined the company's Board of Directors. Additionally, the company announced the appointment of Paige Mahaney, Ph.D., as its new Chief Scientific Officer, bringing over 25 years of experience in pharmaceutical and biotech industries.
The company has also reported initial data from its Phase 1 trial of CFT1946, a molecule targeting BRAF V600 mutant solid tumors, demonstrating successful protein degradation across various doses. Furthermore, C4 Therapeutics achieved a milestone in its collaboration with Biogen (NASDAQ:BIIB), triggering an $8 million payment. Lastly, the company received approval for a clinical trial of CFT8919, a treatment for EGFR L858R-mutated non-small cell lung cancer, in China. These are the recent developments in the company's operations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.